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ABSTRACT
This overview briefly describes current literature findings in ophthalmology 
related to coronavirus disease 2019 (COVID-19) that become a worldwide 
pandemic. It included the current updates related to conjunctivitis that 
believed as the early sign of COVID-19, the effectiveness of conjunctival swab 
in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
compared to naso- or oropharyngeal swab and the long-term side effect 
of chloroquine use to the eyes. The analysis from four current published 
literatures revealed, overall sensitivity of conjunctivitis was 2.42% (CI 95%: 
0.79-5.55) and conjunctival swab was 2.90% (CI 95%: 1.07-6.20). There were no 
current COVID-19-related literatures discussing the side effect of chloroquine 
to the eyes, however, previous literatures revealed there were potential long-
term harmful effects of chloroquine treatment to the eyes.
ABSTRAK
Tinjauan pustaka ini menjelaskan secara singkat temuan-temuan literatur 
terbaru di bidang oftalmologi terkait dengan coronavirus disease 2019 
(COVID-19) yang menjadi pandemi di seluruh dunia. Tinjauan ini mencakup 
temuan terbaru pada konjungtivitis yang dipercaya sebagai tanda awal 
COVID-19, efektivitas swab konjungtiva dalam mendeteksi severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) dibandingkan dengan swab 
naso atau orofaring dan efek samping jangka Panjang penggunaan klorokuin 
pada mata. Analisis dari empat publikasi terbaru menunjukkan sensitivitas 
konjungtivitis adalah 2,42% (CI95%: 0,79-5,55) dan swab konjungtiva adalah 
2,90% (CI95%:1,07-6,20). Tidak ada literatur terbaru terkait COVID-19 saat 
ini yang membahas efek samping klorokuin pada mata, namun kajian 
sebelumnya mengungkapkan ada potensi efek jangka panjang pada mata yang 
membahayakan akibat penggunaan klorouin.
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INTRODUCTION
Many experts believed that 
conjunctivitis as the early sign of 
coronavirus 2019 (COVID-19). It based on 
the findings that some cases of COVID-19 
may have conjunctivitis manifestation 
and upon conjunctival swab of the 
patients, several of them yielded positive 
results for COVID-19 viral nucleic acid.1 
Conjunctival congestion was among 
the least common symptoms occurring 
at only 0.8% even lower than diarrhea 
occurring in 3.8% of the population.2 
There were attempts to find an easier 
way to collect sample of severe acute 
respiratory syndrome 2 (SARS-CoV-2) 
other than from naso- or oropharyngeal 
swab. Conjunctival swab technique 
has been used to obtain conjunctival 
specimens from patients suspected 
infected by SARS-CoV-2. This technique 
aims to collect tears and conjunctival 
secretions from patients. The examiner 
should open the lower lid of each patient 
and wipe the conjunctiva of the patient’s 
lower eyelid fornix using a disposable 
sampling swab without anesthesia.1 
COVID-19 is a new emerging viral 
disease and no antiviral treatments have 
been approved. However, there were 
several attempts have been proposed 
to treat this disease such as lopinavir/
ritonavir (400/100 mg every 12 h) as well 
as the administration of chloroquine (500 
mg every 12 h) or hydroxychloroquine 
(200 mg every 12 h). Therefore, the 
safety issue regarding those regiments to 
the eyes has raised. This study aimed to 
decipher how sensitive is conjunctivitis 
as a sign of COVID-19 and conjunctival 
swab in detecting SARS-CoV-2 as well 
as to inform the potential long-term 
harmful effect of chloroquine use to the 
eyes.
MATERIALS AND METHODS
A systematic literature search was 
undertaken during the period of April-
May 2020 from PUBMED database and 
other additional sources (i.e: Google 
Scholar). PICO framework was used to 
identify the research problems related 
to conjunctivitis, conjunctival swab, and 
chloroquine for literature review (TABLE 
1). Keywords for schematic review were 
conjunctivitis OR ocular AND COVID-19 
OR SARS-CoV-2; Conjunctival swab OR 
ocular AND COVID-19 OR SARS-CoV-2, 
chloroquine OR hydroxychloroquine 
AND COVID-19 OR SARS-CoV-2 (FIGURE 
1). Papers were examined in terms 
of percentages of conjunctivitis 
and positive conjunctival swab in 
COVID-19 as well as current findings of 
chloroquine administration in COVID-19. 
Percentages of conjunctivitis and 
positive conjunctival swab from current 
literature (January 2020-current) were 
analyzed for sensitivity and specificity 
diagnostic tests. 
TABLE 1. PICO framework for identifying the research problems
Variable 
Patients/
Population
Intervention Comparison Outcome
Conjunctivitis COVID-19 N/A
Naso- or 
oropharyngeal swab
Diagnostic value of 
conjunctivitis
Conjunctival Swab COVID-19 N/A
Naso- or 
oropharyngeal swab
Diagnostic value of  
conjunctival swab
Chloroquine COVID-19 Chloroquine
Other treatment for 
COVID-19
Retinotoxicity or other 
ophthalmic side effects
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FIGURE 1. PRISMA chart of systematic review
RESULTS
Diagnostic characteristics analysis 
of conjunctivitis and conjunctival swab 
were sensitivity, specificity, positive, 
predictive value (PPV), negative 
predictive value (NPV), and accuracy. 
TABLE 2 shows the sensitivity and 
specificity of conjunctivitis as the sign of 
COVID 19, and was revealed that overall 
sensitivity and specificity were 2.42 (0.79-
5.55) and 100 (91.59-100), respectively.
TABLE 2. Diagnostic analysis of conjunctivitis in COVID-19.
Variable Xia et al.1 Zhou et al.5 Wu et al.6 Deng et al.7 Overall
Sensitivity
4.0
(0.10-20.35)
1.54
(0.04-8.28)
10.71
(2.27-28.23)
0
(0-4.02)
2.42
(0.79-5.55)
Specificity
100
(39.76-100)
100
(15.81-100)
100
(69.15-100)
100
(85.75-100)
100
(91.59-100)
PPV 100 100 - - 100
NPV
14.29
(13.33-15.29)
3.03
(2.94-3.12)
28.57
(26.03-31.26)
21.05
17.21
(16.91-17.52)
Accuracy
17.24
(5.85-35.77)
4.48
(0.93-12.53)
34.21
(19.63-51.35)
21.05
(13.98-29.69)
18.88
(14.21-24.3)
Note: All data were in percentage (CI95%); PPV: positive predictive value;
NPV: negative predictive value.
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TABLE 3 shows the sensitivity and 
specificity of conjunctival swab as the 
sign of COVID-19. The sensitivity and 
specificity were 2.90 (1.07-6.20) and 100 
(91.59-100), respectively. A very low 
sensitivity means that there were many 
false negative results, and thus many 
cases of COVID-19 were missed when 
using conjunctivitis as sign of COVID-19 
as well as conjunctival swab for SARS-
CoV-2 detection.
TABLE 3. Diagnostic analysis of conjunctival swab in COVID-19
Variable Xia et al.1 Zhou et al.5 Wu et al.6 Deng et al.7 Overall
Sensitivity
3.85
(0.10-19.64)
4.76
(0.99-13.26)
7.14
(0.88-23.50)
0
(0-4.02)
2.90
(1.07-6.20)
Specificity
100
(39.76-100)
100
(36.76-100)
100
(69.15-100)
100
(85.75-100)
100
(91.59-100)
PPV 100 100 100 100
NPV
13.79
(12.90-14.73)
6.25
(5.93-6.58)
27.78
(25.76-29.89) 21.05
17.28
(16.95-17.62)
Accuracy
16.67
(5.64-34.72)
10.45
(4.3-20.35)
31.58
(17.50-48.65)
21.05
(13.98-29.69)
19.28
(14.57-24.73)
Note: All data were in percentage (CI95%); PPV: positive predictive value;
NPV: negative predictive value.
There were no current clinical trials 
investigating the potential side-effect of 
chloroquine treatment for COVID-19 to 
the eyes.
DISCUSSION
Is conjunctivitis the early sign of 
COVID-19?
From four current literature, 
the diagnostic test analysis revealed 
that conjunctivitis showed a very 
low sensitivity.  Therefore, many 
cases of COVID-19 might be missed 
when conjunctivitis is used as sign to 
diagnose COVID-19. A case report of a 
30 y.o patient with confirmed COVID-19 
developed bilateral conjunctivitis on day 
13 with a positive conjunctival swab for 
COVID-19.3 Another case reported ocular 
manifestation of keratoconjunctivitis 
occurred as the initial medical 
presentation of COVID-19. The patient’s 
main symptoms were red eye with 
watery discharge and upon conjunctival 
swab, the result yielded positive for 
COVID-19. Despite the positive COVID-19 
result, the patient had a mild respiratory 
symptom without fever.4
It was also found that conjunctiva 
and corneal epithelial also expressed 
ACE2 although the expression was only 
slight. It was likely caused the binding 
of COVID-19 which explains the ocular 
findings of COVID-19 viral nucleic acid.8 
Peng and Zhou9 concluded that COVID-19 
is less likely transmitted via conjunctiva 
which means the detection of COVID-19 
in tears and conjunctival secretions 
in patients exhibiting symptoms of 
conjunctivitis is a coincident event rather 
than causative of COVID-19 infection of 
the conjunctiva.9
Is conjunctival swab effective in 
detecting SARS-CoV-2?
Conjunctival swab technique is 
used to obtain conjunctival specimens 
which consists of tears and conjunctival 
secretions samples taken from lower 
eyelid fornix. In the present literature 
review, similar as the conjunctivitis 
result low sensitivity in conjunctival 
swab suggested that conjunctival swab 
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diagnostic value was very low for SARS-
CoV-2 detection. Furthermore, low 
negative predictive value reveals that 
when conjunctival swab yielded no virus 
detected, the patient still has very high 
probability having COVID-19.
Numerous studies have previously 
found no superiority of conjunctival 
swab compared to nasopharyngeal 
swab. For instance, a cross-sectional 
study of 72 patients with laboratory 
confirmed COVID-19 RT-PCR assay 
showed only 2 patients had the ocular 
manifestation of conjunctivitis and only 
one patient had positive COVID-19 upon 
conjunctival swab.10  From the experience 
of SARS-COV, there was a prospective 
interventional case series study that was 
conducted to identify the SARS-CoV virus 
in tear secretions and conjunctival cells 
of patients that is confirmed positive 
SARS-CoV in Prince of Wales Hospital, 
Hongkong. The study result showed that 
17 patients are confirmed positive after 
being tested with paired convalescent 
sera. Then, the specimen sample 
including nasopharyngeal aspirate 
and stool, tear swab, and conjunctival 
scraping were taken from these patients. 
Among these 17 patients, there were 
five samples from nasopharyngeal 
aspirate and stool specimens that were 
tested positive using RT-PCR, but there 
were no specimens from tear swab and 
conjunctival scraping that are tested 
positive. This could be caused by the 
RT-PCR test itself. RT-PCR is known to 
be very specific but lacks sensitivity, 
so the negative test result can be 
false negative and do not exclude the 
presence of the virus. The study could 
not completely exclude the presence of 
virus in tear secretion, but it was clear 
that conjunctival swabs and conjunctival 
scraping are not useful samples for 
confirming or excluding the diagnosis of 
SARS-CoV.11
Although the risk of ocular infection 
of COVID-19 was low, the transmission 
of COVID-19 through the ocular surface 
must not be ignored. The infectious 
droplets may easily contaminate the 
conjunctival epithelium. It was also 
recommended for all ophthalmologists 
to wear protective eyewear in examining 
suspected cases.12
Is chloroquine as COVID-19 treatment 
is safe for eyes?
Chloroquine is a medication used 
to prevent and cure malaria but now 
is only used in areas where malaria 
remains sensitive to its effects and 
use as prophylaxis in areas that are 
resistant to this medication.13 Besides 
the antimicrobial effect, chloroquine 
was found to be efficient in inhibiting 
virus replication cycles such as rabies 
virus, poliovirus, HIV, hepatitis A 
virus, hepatitis C virus, influenza A 
and B viruses, influenza A H5N1 virus, 
Chikungunya virus, Dengue virus, Zika 
virus, Lassa virus, Hendra and Nipah 
viruses, Crimean–Congo hemorrhagic 
fever virus and Ebola virus, as well as 
various DNA viruses such as hepatitis B 
virus and herpes simplex virus.14
Chloroquine has multiple 
mechanisms on the virus, especially 
in coronavirus. By interfering with 
viral particles binding to their cellular 
cell surface receptor. Chloroquine can 
inhibit a step of the viral cycle life. 
Chloroquine can also interfere with the 
post-translational modification of viral 
proteins. Besides interfering with the life 
cycle of the virus, chloroquine can impair 
the proper maturation of viral protein 
by pH modulation.14  In vitro study found 
evidence of the ability of chloroquine to 
inhibit SARS-CoV-2 activity.15
The empirical evidence for the 
effectiveness of chloroquine in COVID-19 
is currently very limited but the first 
clinical trial data were published 
on the March 17th 2020. The study 
showed all patients who were treated 
with a combination of chloroquine 
and azithromycin tested negative on 
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day 6. The authors argued that this 
finding speaks to the effectiveness of 
chloroquine and a potential synergistic 
effect of its combined treatment with 
azithromycin.16
It is not fully clear how chloroquine 
caused toxicity in the eye. In one study, 
high doses have an acute effect on retinal 
cell metabolism. Studies have shown 
that the drug affects the metabolism of 
retinal cells and also binds to melanin 
in the retinal, which could explain the 
persistent toxicity after discontinuation 
of the medication.17 This can happen 
because chloroquine binds to melanin 
within retinal pigment epithelial cells, 
and it is resulting in long term damage 
to macula photoreceptors (FIGURE 2). 
These mechanisms may lead to clinically 
characteristic “bull's eye” maculopathy 
after chronic exposure to both agents 
even in the safe dose, in early stages is 
reversible but leads to irreversible loss 
of central vision in long term, reduced 
visual acuity, scotoma formation, 
and/or color vision deficits.18 Bull’s-
eye maculopathy caused by a ring of 
parafoveal retinal depigmentation that 
spared a foveal island.19
FIGURE 2. Proposed pathophysiology in chloroquine retinal toxicity17-19
American Academy of 
Ophthalmology reported that the 
most significant major risk factors for 
chloroquine retinal toxicity are high dose 
and long duration of use.19  The maximum 
daily dose of chloroquine is ≤2.3 mg/kg of 
real body weight. But various treatment 
guidelines worldwide are well beyond 
the recommended dosage regimen.20 
Although the fact that doses for 
chloroquine exceed the recommended 
dosage regimen, the treatment may still 
be considered relatively safe for retinal 
toxicity. This is because irreversible 
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retinal damage and visual loss, requires 
exposure for a long period, generally 
above five years. The recommendation 
suggested for the screening for retinal 
toxicity from chloroquine is within the 
first year of use and after a year of use 
for chloroquine and  screening should 
be conducted sooner if the major risk 
factors are present.21 In this pandemic 
condition, routine baseline ocular 
examination for patients with COVID-19 
is not absolutely necessary but should 
be considered if the number of medical 
personnel is adequate. But it is necessary 
to take a history of ocular disease in 
patients who are older than 50 years 
before giving a treatment, especially 
macular disease.20
CONCLUSION
The analysis from the present 
literature review revealed that from 
four current published literatures, the 
overall sensitivity of conjunctivitis 
and conjunctival swab are very low. 
There are no current COVID-19-related 
literature discussing the side effect 
of chloroquine to the eyes, although 
previous literature suggested there is 
potential long-term harmful effect of 
chloroquine treatment for COVID-19 to 
the eyes.
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